Acadia Stock Analysis

ACAD -  USA Stock  

USD 25.85  0.18  0.69%

The latest indifference towards the small price fluctuations of Acadia Pharmaceutica could raise concerns from shareholders as the firm it trading at a share price of 25.85 on 1,008,119 in volume. The company executives did not add any value to Acadia Pharmaceutica investors in May. However, most investors can still diversify their portfolios with Acadia Pharmaceutica to hedge their inherited risk against high-volatility market scenarios. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.35. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Acadia Pharmaceutica partners.
Please continue to Trending Equities.

Search Stock Analysis 

 
Refresh
The Acadia Pharmaceutica stock analysis report makes it easy to digest most publicly released information about Acadia Pharmaceutica and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Acadia stock analysis module also helps to analyze the Acadia Pharmaceutica price relationship with some important fundamental indicators such as market cap and management efficiency.

Acadia Stock Analysis Notes

About 95.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 1.79. Acadia Pharmaceutica next dividend is scheduled to be issued on the 30th of June 2010. ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California. Acadia Pharmaceutica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 601 people. For more info on Acadia Pharmaceutica please contact the company at 858 558-2871 or go to www.acadia-pharm.com.

Acadia Pharmaceutica Quarterly Cost of Revenue

2.19 MillionShare

Acadia Pharmaceutica Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Acadia Pharmaceutica's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Acadia Pharmaceutica or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Acadia Pharmaceutica has very high historical volatility over the last 90 days
Acadia Pharmaceutica is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 441.76 M. Net Loss for the year was (281.58 M) with profit before overhead, payroll, taxes, and interest of 154.88 M.
Acadia Pharmaceutica currently holds about 631.96 M in cash with (136.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.95.
Acadia Pharmaceutica has a frail financial position based on the latest SEC disclosures
Over 95.0% of the company shares are held by institutions such as insurance companies
Latest headline from www.nasdaq.com: POLL-Oil demand rebound to prevail over potential Iran, India headwinds - Nasdaq

Acadia Pharmaceutica Upcoming and Recent Events

Earnings reports are used by Acadia Pharmaceutica to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Acadia Pharmaceutica previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report4th of August 2021
Next Earnings Report3rd of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End23rd of February 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Acadia Largest EPS Surprises

Earnings surprises can significantly impact Acadia Pharmaceutica's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2013-08-06
2013-06-30-0.09-0.11-0.0222 
2013-03-12
2012-12-31-0.09-0.11-0.0222 
2012-08-08
2012-06-30-0.12-0.10.0216 
View All Earnings Estimates

Acadia Pharmaceutica SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Acadia Pharmaceutica prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Acadia Pharmaceutica investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Acadia Pharmaceutica specific information freely available to individual and institutional investors to make a timely investment decision.
5th of May 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
5th of April 2021
Financial Statements and Exhibits. Other Events. Regulation FD Disclosure
View
8th of March 2021
Financial Statements and Exhibits. Other Events
View
24th of February 2021
Financial Statements and Exhibits. Results of Operations and Financial Condition
View
16th of February 2021
Unclassified Corporate Event
View
10th of February 2021
Unclassified Corporate Event
View
8th of February 2021
Unclassified Corporate Event
View
27th of January 2021
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
View

Acadia Pharmaceutica Thematic Classifications

In addition to having Acadia Pharmaceutica stock in your portfolios, you can add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your favorite investment opportunity, you can then obtain an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility. If you are a result-oriented investor, you can benefit from optimizing one of our existing themes to build an efficient portfolio against your specific investing outlook.
Biotech IdeaBiotech
Biotechnology and pharmaceuticals production and services

Acadia Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Acadia Pharmaceutica is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Acadia Pharmaceutica backward and forwards among themselves. Acadia Pharmaceutica's institutional investor refers to the entity that pools money to purchase Acadia Pharmaceutica's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Baker Bros Advisors LpCommon Shares41.9 M1.1 B
Fmr LlcCommon Shares17.2 M443.4 M
Vanguard Group IncCommon Shares10.9 M280.2 M
Price T Rowe Associates IncCommon Shares8.4 M215.5 M
Blackrock IncCommon Shares7.4 M191 M
Janus Henderson Group PlcCommon Shares5.4 M138.7 M
State Street CorpCommon Shares3.2 M82.8 M
Note, although Acadia Pharmaceutica's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Acadia Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 4.14 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Acadia Pharmaceutica's market, we take the total number of its shares issued and multiply it by Acadia Pharmaceutica's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Acadia Profitablity

Acadia Pharmaceutica's profitability indicators refer to fundamental financial ratios that showcase Acadia Pharmaceutica's ability to generate income relative to its revenue or operating costs. If, let's say, Acadia Pharmaceutica is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Acadia Pharmaceutica's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Acadia Pharmaceutica's profitability requires more research than a typical breakdown of Acadia Pharmaceutica's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
The company has Profit Margin (PM) of (63.74) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (52.92) %, which suggests for every $100 dollars of sales, it generated a net operating loss of -0.53.
Last ReportedProjected for 2021
Return on Investment(43.22) (46.63) 
Return on Average Assets(0.36) (0.39) 
Return on Average Equity(0.44) (0.47) 
Return on Invested Capital(0.74) (0.80) 
Return on Sales(0.64) (0.69) 

Management Efficiency

The entity has return on total asset (ROA) of (18.66) % which means that it has lost $18.66 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (42.47) %, meaning that it created substantial loss on money invested by shareholders. Acadia Pharmaceutica management efficiency ratios could be used to measure how well acadia pharmaceutica manages its routine affairs as well as how well it operates its assets and liabilities. As of June 20, 2021, Return on Investment is expected to decline to -46.63. In addition to that, Return on Average Assets is expected to decline to -0.39. Acadia Pharmaceutica Goodwill and Intangible Assets are projected to decrease significantly based on the last few years of reporting. The past year's Goodwill and Intangible Assets were at 1.11 Million. The current year Revenue to Assets is expected to grow to 0.61, whereas Current Assets are forecasted to decline to about 579.6 M.
Last ReportedProjected for 2021
Book Value per Share 3.98  3.67 
Enterprise Value over EBIT(29.00) (31.29) 
Enterprise Value over EBITDA(29.08) (31.38) 
Price to Book Value 13.55  12.03 
Tangible Assets Book Value per Share 4.97  4.39 
Enterprise Value8.1 B8.7 B
Tangible Asset Value781.5 M619.1 M

Technical Drivers

As of the 20th of June, Acadia Pharmaceutica shows the mean deviation of 2.25, and Risk Adjusted Performance of 0.0029. Acadia Pharmaceutica technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to analyze nineteen technical drivers for Acadia Pharmaceutica, which can be compared to its rivals. Please confirm Acadia Pharmaceutica mean deviation, standard deviation, treynor ratio, as well as the relationship between the downside deviation and information ratio to decide if Acadia Pharmaceutica is priced correctly, providing market reflects its regular price of 25.85 per share. Given that Acadia Pharmaceutica has jensen alpha of (0.019902), we suggest you to validate Acadia Pharmaceutica's prevailing market performance to make sure the company can sustain itself at a future point.

Acadia Pharmaceutica Price Movement Analysis

The output start index for this execution was thirteen with a total number of output elements of fourty-eight. The Moving Average is predictive technique used to analyze Acadia Pharmaceutica price data points by creating a series of averages of different subsets of Acadia Pharmaceutica entire price series. View also all equity analysis or get more info about all moving average overlap studies indicator.

Acadia Pharmaceutica Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Acadia Pharmaceutica insiders, such as employees or executives, is commonly permitted as long as it does not rely on Acadia Pharmaceutica's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Acadia Pharmaceutica insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Austin Kim over two months ago via Macroaxis 
Sale by Austin Kim of 678 shares of Acadia Pharmaceutica
Elena Ridloff over three months ago via Macroaxis 
Sale by Elena Ridloff of 2051 shares of Acadia Pharmaceutica
Srdjan Stankovic over three months ago via Macroaxis 
Exercise or conversion by Srdjan Stankovic of 700 shares of ACADIA Pharmaceuticals subject to Rule 16b-3
Elena Ridloff over three months ago via Macroaxis 
Exercise or conversion by Elena Ridloff of 1016 shares of ACADIA Pharmaceuticals subject to Rule 16b-3
Srdjan Stankovic over six months ago via Macroaxis 
Exercise or conversion by Srdjan Stankovic of 6250 shares of ACADIA Pharmaceuticals subject to Rule 16b-3
Michael Yang over six months ago via Macroaxis 
Exercise or conversion by Michael Yang of 2500 shares of ACADIA Pharmaceuticals subject to Rule 16b-3
Garofalo Elizabeth A over six months ago via Macroaxis 
Acquisition by Garofalo Elizabeth A of 3837 shares of ACADIA Pharmaceuticals subject to Rule 16b-3
Baker Bros Advisors Lp over six months ago via Macroaxis 
Purchase by Baker Bros Advisors Lp of 5503 shares of ACADIA Pharmaceuticals
Stephen Davis over six months ago via Macroaxis 
Exercise or conversion by Stephen Davis of 15625 shares of ACADIA Pharmaceuticals subject to Rule 16b-3
Michael Yang over six months ago via Macroaxis 
Exercise or conversion by Michael Yang of 14750 shares of ACADIA Pharmaceuticals subject to Rule 16b-3
Michael Yang over six months ago via Macroaxis 
Sale by Michael Yang of 16150 shares of ACADIA Pharmaceuticals
Kihara James over six months ago via Macroaxis 
ACADIA Pharmaceuticals exotic insider transaction detected

Acadia Pharmaceutica Technical and Predictive Indicators

Acadia Pharmaceutica Forecast Models

Acadia Pharmaceutica time-series forecasting models is one of many Acadia Pharmaceutica's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Acadia Pharmaceutica's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Acadia Pharmaceutica Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Acadia Pharmaceutica stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Acadia shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Acadia Pharmaceutica. By using and applying Acadia Stock analysis, traders can create a robust methodology for identifying Acadia entry and exit points for their positions.
Last ReportedProjected for 2021
Operating Margin(64.87) (70.00) 
EBITDA Margin(0.63) (0.68) 
Gross Margin 0.98  0.92 
Profit Margin(0.64) (0.69) 
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California. Acadia Pharmaceutica operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 601 people.

Current Acadia Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Acadia analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Acadia analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
29.06Hold16Odds
Acadia Pharmaceutica current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Acadia analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Acadia stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Acadia Pharmaceutica, talking to its executives and customers, or listening to Acadia conference calls.
Acadia Analyst Advice Details

Acadia Stock Analysis Indicators

Acadia Pharmaceutica stock analysis indicators help investors evaluate how Acadia Pharmaceutica stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Acadia Pharmaceutica shares will generate the highest return on investment. By understating and applying Acadia Pharmaceutica stock analysis, traders can identify Acadia Pharmaceutica position entry and exit signals to maximize returns.
Quick Ratio6.44
Fifty Two Week Low19.20
Revenue Growth23.10%
Shares Short Prior Month6.52M
Average Daily Volume Last 10 Day2.09M
Average Daily Volume In Three Month2.18M
Shares Percent Shares Out4.99%
Gross Margins35.06%
Short Percent Of Float8.66%
Forward Price Earnings-33.14
Float Shares117.75M
Fifty Two Week High58.72
Enterprise Value To Ebitda-11.01
Fifty Day Average22.13
Two Hundred Day Average37.60
Enterprise Value To Revenue5.75
Please continue to Trending Equities. Note that the Acadia Pharmaceutica information on this page should be used as a complementary analysis to other Acadia Pharmaceutica's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Money Managers module to screen money managers from public funds and ETFs managed around the world.

Complementary Tools for Acadia Pharmaceutica Stock analysis

When running Acadia Pharmaceutica price analysis, check to measure Acadia Pharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acadia Pharmaceutica is operating at the current time. Most of Acadia Pharmaceutica's value examination focuses on studying past and present price action to predict the probability of Acadia Pharmaceutica's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Acadia Pharmaceutica's price. Additionally, you may evaluate how the addition of Acadia Pharmaceutica to your portfolios can decrease your overall portfolio volatility.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Equity Analysis
Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Go
The market value of Acadia Pharmaceutica is measured differently than its book value, which is the value of Acadia that is recorded on the company's balance sheet. Investors also form their own opinion of Acadia Pharmaceutica's value that differs from its market value or its book value, called intrinsic value, which is Acadia Pharmaceutica's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Acadia Pharmaceutica's market value can be influenced by many factors that don't directly affect Acadia Pharmaceutica underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Acadia Pharmaceutica's value and its price as these two are different measures arrived at by different means. Investors typically determine Acadia Pharmaceutica value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Acadia Pharmaceutica's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.